The Quiet Report  ·  Evidence Review  ·  Quietaa  ·  May 2026

60-Day Trial

Quietaa   ›   Evidence Review   ›   tVNS Comparison Guide

EDITORIAL  BUYER’S-GUIDE

LONG COVID . DYSAUTONOMIA

Rated 4..5/5   |   Loved by 10K+ customers

Cervical and Auricular Vagus Nerve Stimulators for Long COVID and Dysautonomia: A Comparison of Quietaa, Nurosym, Pulsetto, and Truvaga

Four FDA-uncleared, research-anchored devices. Different modalities. Different price structures. Different evidence bases. We make one of them. We have included it in this comparison because no one else was writing this guide. Where our device is not the right fit, we say so.

Title

WRITTEN BY

THE QUIETAA TEAM

PUBLISHED

MAY 2026

LAST UPDATED

MAY 25, 2026

READ TIME

12-MINUTE

01

WHY THIS

GUIDE EXISTS

Why this guide exists

If you arrived at this page, you most likely arrived by way of a research paper, a long COVID subreddit, a Substack newsletter, or a dysautonomia community thread. You are not browsing. 

 

You are evaluating. You have probably already read at least one of the published papers on transcutaneous vagus nerve stimulation in post-viral fatigue, POTS, or autonomic dysregulation. You have probably already heard the names of the four devices in the headline above. You may have already tried one of them. 

 

What you have not had, until now, is a comparison written by someone with a stake in the answer who is willing to admit it. 

 

This is that comparison.

 

 The four devices below — Nurosym, Pulsetto, Truvaga, and Quietaa — are the cervical or auricular non-invasive vagus nerve stimulators with meaningful published research bases in long COVID, dysautonomia, and related autonomic conditions. None of them are FDA-cleared as medical treatments for these conditions. Some have CE-mark or related regulatory recognition in Europe. All of them are general wellness devices in the United States. We have excluded skin-conductance feedback devices (Apollo Neuro), vibratory infrasonic devices (Sensate), and consumer EMS devices that do not target the vagus nerve specifically. A short list of what we did not include and why sits at the end of the guide.

 

 A note on the population this guide is written for: people with long COVID, post-viral fatigue, dysautonomia, POTS, or related autonomic dysregulation. If your starting point is generalized anxiety with normal autonomic function, this guide is not optimised for you — and a different framing would probably serve you better. The reasoning here is built around the long-haul community specifically.
Title

02

DISCLOSURE &

WHAT'S AT STAKE

Disclosure: who we are and what is at stake

This guide was written by the team that built Quietaa. We made it because the cervical-tVNS comparison content we wanted to read for our own community did not exist — what existed was either affiliate-driven listicle pages with manufactured “Best of 2026” rankings, or brand sites that explained why their device was best without referencing any of the others honestly. 

 

You should know two things going in. 

 

First, we have a financial stake in the answer. If you buy Quietaa, our team gets paid. We have written this guide knowing that, and we have tried to keep it honest enough that you would forgive us for that fact.

 

 Second, we will tell you when Quietaa is not the right answer. Three of the four products below — including ours — could be the right choice depending on your situation. Where Nurosym is the better fit, we say so. Where Truvaga is the better fit, we say so. The decision matrix at the bottom of this guide is not a sales tool; it is the honest filter you would apply if you were on our team. 

 

If that posture works for you, the rest of the guide will be useful. If it does not, the threads at r/dysautonomia and r/covidlonghaulers contain consumer-written comparisons that may serve you better.
Title

03

TECHNICAL 

PRIER

A brief technical primer — cervical vs auricular tVNS

There are two non-invasive ways to stimulate the vagus nerve through the skin

 

Auricular tVNS

 

The first is auricular tVNS — also called taVNS or aVNS. It targets the auricular branch of the vagus nerve, which surfaces inside the concha and tragus of the ear. A device clips to the ear and delivers a low-frequency electrical pulse to that branch. Of the four devices in this guide, only Nurosym is auricular. 

Nurosym

Cervical tVNS

 

The second is cervical tVNS — sometimes called tcVNS or ctVNS. It targets the cervical portion of the vagus nerve, which runs down both sides of the neck inside the carotid sheath. A device sits on the neck (collar-style for bilateral devices, handheld for unilateral devices) and delivers an electrical pulse through the skin to the nerve. Pulsetto, Truvaga, and Quietaa are all cervical — Pulsetto and Quietaa are bilateral collars; Truvaga is unilateral and handheld. 

Pulsetto

Truvaga

Quietaa

The published research on the two modalities overlaps but is not identical. Auricular tVNS has the deeper history in inflammatory and gastrointestinal indications. Cervical tVNS has stronger data in cardiovascular, autonomic, and migraine indications. For long COVID and dysautonomia specifically, the evidence base spans both — Nurosym (auricular) and the cervical devices have all accumulated meaningful pilot and observational data in this population.

 

What matters for your decision: the two modalities feel different to use, are typically protocolled differently, and may suit different people. The product cards below address this for each.

Cervical tVNS targets the vagus nerve along the neck; auricular tVNS targets the same nerve’s branch inside the ear.
Title

Across multiple pilot studies of cervical and auricular tVNS in long COVID, dysautonomia, and POTS populations, statistically meaningful improvements in HRV, autonomic balance, and subjective symptom scores have been documented within 4 to 12 weeks of consistent use.

Sample sizes in this literature are typically small (n = 25–80 per study). A multi-centre RCT on auricular tVNS for long COVID is ongoing as of mid-2026.
 

Source: published research in Frontiers in Neurology, Brain Stimulation, Bioelectronic Medicine, and Neuromodulation, 2021–2025.

 the four devices, compared

The cards below use the same structure for each product. The fields are designed to be scannable side-by-side. Each card ends with a direct outbound link to that manufacturer’s product page. Quietaa is positioned last in the list deliberately — this is not a ranked guide, and we did not want the visual hierarchy to imply one.

Nurosym

MANUFACTURER

Parasym Ltd. (United Kingdom)

MODALITY

Auricular tVNS (ear clip targeting tragus / cymba conchae)

FORM FACTOR

Handheld controller wired to an ear clip electrode

TREATMENT PROTOCOL

Typically 30 to 60 minutes per session, once or twice daily. Sessions feel substantial — many users describe a strong, distinct sensation at the ear and report noticeable post-stim fatigue effects in the first weeks of use as the system adjusts.

EVIDENCE BASE

Nurosym has accumulated the deepest clinical research footprint of any consumer-available tVNS device. Multiple pilot and observational studies in long COVID specifically have used Nurosym or its predecessor platform, including work on heart rate variability, inflammatory cytokines, and post-COVID fatigue. Parasym maintains a clinical advisory board and a publications page; the citations are real and verifiable. Sample sizes are pilot-scale (n = 25–80 in most studies). A multi-centre RCT in long COVID is ongoing as of mid-2026.

REGULATORY STATUS

CE-marked in Europe under medical device classification. Not FDA-cleared as a medical treatment in the United States; sold stateside as a general wellness device.

PRICE STRUCTURE

Approximately £549 / $649 USD upfront. No subscription. Annual electrode pad replacements run roughly £40–£50. (Verify current pricing on Parasym’s site.)

RETURN POLICY

30-day money-back guarantee. (Verify current terms on Parasym’s site at time of purchase.)

BEST FOR

Long COVID and dysautonomia patients who want the device with the strongest clinical research footprint and are not deterred by the higher upfront cost. Patients whose clinicians are already familiar with Nurosym specifically. Patients who tolerate longer sessions well

NOT FOR

Patients who need the device to be affordable indefinitely (the upfront cost is real). Patients who prefer shorter sessions. Patients who find ear-clip devices uncomfortable.

£549 / ~$649 USD · No subscription

Pulsetto

MANUFACTURER

Pulsetto (European)

MODALITY

Bilateral cervical tVNS (collar-style, worn around the neck)

FORM FACTOR

Wearable neck collar with paired electrodes

TREATMENT PROTOCOL

4 to 20 minute sessions, typically once or twice daily depending on the selected programme. Sessions are short and tolerable compared with auricular protocols.

EVIDENCE BASE

Pulsetto’s published research base is more limited than Nurosym’s. Most of the data referenced on the brand site is company-collected user reporting rather than peer-reviewed clinical trials. The underlying modality — bilateral cervical tVNS — has independent clinical research validating it (much of it on the gammaCore / electroCore platform; see Truvaga below), but Pulsetto-specific clinical trials are scarce. The mechanism is real and well-documented; this particular brand’s evidence footprint is thinner than Nurosym’s.

REGULATORY STATUS

Not FDA-cleared as a medical treatment. Sold as a general wellness device.

PRICE STRUCTURE

Approximately $478 retail upfront, frequently discounted to around $278 on the brand site. Pulsetto operates a monthly subscription (“Pulsetto Premium”) for access to the full programme library on its companion app; without the subscription, a more limited set of sessions is available. Annual subscription costs run roughly $96–$144 depending on tier. Realistic five-year lifetime cost: $750–$1,000+. (Verify current pricing.)

RETURN POLICY

30-day money-back guarantee. (Verify current terms.)

BEST FOR

Patients who want a cervical device at a lower upfront cost than Truvaga or Nurosym and are comfortable with app-driven programming. Patients who would actually use additional guided content and find a monthly subscription cost acceptable.

NOT FOR

Patients with subscription fatigue. Patients who want the longest independent clinical evidence base. Patients who want to use the device without an app paired to it.

~$278–$478 + ~$96–$144/yr subscription

Truvaga

MANUFACTURER

electroCore, Inc. (NASDAQ: ECOR), United States

MODALITY

Unilateral cervical tVNS (handheld, pressed against one side of the neck)

FORM FACTOR

Handheld device

TREATMENT PROTOCOL

Two two-minute stimulations per session, typically used 2 to 4 times daily. The session protocol is markedly shorter than the other three devices in this guide.

EVIDENCE BASE

Truvaga is the consumer-positioned product from electroCore, the manufacturer behind gammaCore — the only FDA-cleared non-invasive cervical vagus nerve stimulator on the market. (gammaCore is cleared for treatment of migraine and episodic cluster headache; Truvaga is a separate product and is not.) The shared underlying platform means a substantial body of cervical-tVNS clinical research underlies the modality, though Truvaga as a specific product has its own emerging dataset distinct from gammaCore’s clearances. For long COVID specifically, the cervical-tVNS evidence base is growing but younger than the auricular evidence base.

REGULATORY STATUS

Truvaga is not FDA-cleared as a medical treatment; it is sold as a general wellness device. The sibling product gammaCore has FDA clearances for specific neurological indications; those clearances do not transfer to Truvaga.

PRICE STRUCTURE

Truvaga operates both a subscription model and a one-time-purchase “Plus” model as of mid-2026. The Plus model is approximately $379–$499 upfront with no recurring fee; the subscription model is lower upfront but compounds over time. (Verify current pricing on the Truvaga site.)

RETURN POLICY

30-day satisfaction guarantee. (Verify current terms.)

BEST FOR

Patients who want the shortest sessions available — two minutes is genuinely fast when fatigue is the limiting factor. Patients drawn to the manufacturer with the strongest clinical pedigree in non-invasive cervical vagus nerve stimulation broadly. Patients whose clinician is familiar with electroCore’s platform

NOT FOR

Patients who prefer hands-free sessions and bilateral stimulation (Truvaga is handheld and unilateral). Patients put off by the historical subscription model who haven’t reviewed current pricing options.

~$379–$499 (Plus) · Subscription option available

Quietaa

MANUFACTURER

Quietaa

MODALITY

Bilateral cervical tVNS (collar-style, worn around the neck)

FORM FACTOR

Wearable neck collar with paired electrodes — fundamentally the same form factor as Pulsetto, with differences in fit, finish, electrode design, and the absence of a paired app

TREATMENT PROTOCOL

10 to 20 minute sessions, recommended once or twice daily. Bilateral simultaneous stimulation, five intensity levels, no app required — the session library is on the device.

EVIDENCE BASE

Quietaa uses the same underlying modality — bilateral transcutaneous cervical vagus nerve stimulation — that the cervical-tVNS research base is built on. We do not have Quietaa-specific clinical trials yet. We say so directly because we read the same papers our buyers read, and we are not going to claim research we do not have. What we do have is the same fundamental mechanism, electrode placement, and pulse profile that the underlying research in Frontiers in Neurology, Brain Stimulation, and Bioelectronic Medicine has documented for cervical tVNS. The brand-specific clinical research will accumulate over time; we are committed to publishing real data, not company-collected testimonials.

REGULATORY STATUS

Not FDA-cleared as a medical treatment. Sold as a general wellness device.

PRICE STRUCTURE

$299 USD upfront. No subscription. No app-locked content. No annual access fees. The session library is on the device and stays free for the life of the device. Replacement electrode pads run approximately $30–$40 per year depending on usage. Realistic five-year lifetime cost: $450–$500 — roughly half the lifetime cost of the next-cheapest comparable cervical device.

RETURN POLICY

60-day at-home trial. Free return shipping both ways. No restocking fee. No questions beyond an email.

BEST FOR

Patients who want the bilateral cervical modality without the subscription model that has come to define this segment. Patients who would use a 60-day trial honestly. Patients sensitive to the lifetime cost compounding of subscription-based devices. Patients in active recovery who need to use the device daily, indefinitely, without paying for sessions individually.

NOT FOR

Patients who specifically want the deepest independent clinical research base (Nurosym remains the strongest there). Patients whose clinician has prescribed a specific named device. Patients who want auricular rather than cervical stimulation.

$299 upfront · No subscription · 60-day trial

Visit Quietaa →

Across the four devices in this guide, the difference in 5-year lifetime cost between the highest and lowest option is approximately $550. The difference in return-window length is 30 days.

Long COVID and dysautonomia recovery is measured in weeks to months. Cervical tVNS studies typically report meaningful HRV change within 4 weeks and clinical-symptom change over 6 to 12 weeks. A 30-day return window may not be long enough to evaluate the device in this population.

 

Source: Lifetime cost calculations based on each manufacturer’s published pricing as of May 2026.

 How to choose between the four

The honest filter most of our team would apply, if we were buying for ourselves today:

1. Choose Nurosym if

Your clinician is familiar with it specifically. You want the device with the deepest independent clinical research footprint in long COVID and dysautonomia. The £549 upfront cost is acceptable, and you tolerate longer sessions well.

2. Choose Truvaga if

You want the shortest possible sessions (two minutes is meaningful when daily fatigue is the limiting factor). You are drawn to electroCore’s clinical pedigree in non-invasive cervical vagus nerve stimulation more broadly. The current Truvaga pricing model on their site works for your situation.

3. Choose Pulsetto if

You want the bilateral cervical modality at the lowest possible upfront cost and the subscription content genuinely appeals to you. You are comfortable with the app-paired experience and the lifetime cost it implies.

 

4. Choose Quietaa if

You want the bilateral cervical modality without a subscription, with the longest at-home trial in the category, and the lowest lifetime cost. You would use a 60-day window honestly and return the device if it does not move the needle for you.

If two of these statements are true for you, the order they are listed in tells you which to start with. If none of them are true for you, you may not need a device in this category right now — and we would rather you not buy one than buy the wrong one.

What we did not include — and why

A few notable absences that deserve a sentence.

Apollo Neuro 

Not a vagus nerve stimulator. It uses low-frequency vibration delivered through a wrist or ankle band. The mechanism is interoceptive touch-based signalling, not direct nerve stimulation. It may help some people; it does not belong in a tVNS comparison.
Title

Sensate 

Also not a vagus nerve stimulator. It is a chest-worn vibratory device using infrasonic resonance. Same reasoning — different mechanism, different category.
Title

gammaCore

The FDA-cleared cervical tVNS device from electroCore. It is a prescription medical device, not a consumer product. If your clinician offers it for migraine or cluster headache, that is a different and separate conversation worth having.
Title

Hoolest VeRelief

A credible smaller-company entrant. We have excluded it from this comparison primarily on independent research-base depth and clinical adoption to date, but it is worth knowing about and may belong in a future revision of this guide.

A note on the 60-day trial argument

The return windows on these four devices diverge meaningfully, and the divergence matters more in this population than the rest of the consumer wellness market.

 

Long COVID and dysautonomia recovery is not measured in days. It is measured in weeks to months. The published research on cervical and auricular tVNS shows meaningful HRV change within two to four weeks of consistent use, and clinical-symptom change typically reported over six to twelve weeks. A 30-day return window — which is the industry standard among the other three devices in this guide — does not give a long-haul patient enough time to know whether the device is working.

 

This is not an accusation of bad faith on the part of the other manufacturers. 30 days is the e-commerce default. It works for most consumer products. It does not work for this population.

 

Quietaa ships with a 60-day at-home trial because that is the minimum honest window in which a long COVID or dysautonomia patient can evaluate this category for themselves. The trial is free both ways. The decision to keep the device is yours after 60 days of using it; the decision to send it back, free, is also yours.

Closing

If you have read this far, you are exactly the buyer this guide was written for. 

 

The decision matrix above is the honest one. Quietaa is the right answer in some cases. It is not the right answer in others. We have tried to say so clearly. The fact that you are evaluating this category seriously, eighteen months in or three months in, deserves a real comparison rather than a sales page. 

 

If you want to start with Quietaa and use the 60-day window to evaluate it against your own HRV, your own symptoms, and your own recovery trajectory, the button below will take you to the product page. If you want to start somewhere else, the per-product links above are direct to each manufacturer. 

 

Either way, you are doing the right thing by evaluating this seriously. The work you have already put into your own recovery is the work that earned you the right to ask the harder questions.

QUIETAA . 60-DAY AT-HOME TRIAL 

Start a 60-Day Trial of Quietaa →

$299 upfront. No subscription. 60-day at-home trial. Free shipping both ways.

Rated 4..5/5   |   Loved by 10K+ customers

60-day guarantee | Free shipping | Ships worldwide | Secure Checkout

QUIETAA . Bilateral cervical tVNS. The evidence base. The 60-day trial. No subscription.

Same modality. Half the lifetime cost. None of the surprises.

Privacy Policy

Terms of Service

© 2026 Quietaa. General wellness device. Not FDA-cleared as a medical treatment.